Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa

Core Insights - Nxera Pharma has received a milestone payment of US$3.6 million from Centessa Pharmaceuticals due to the achievement of an early development milestone for the investigational drug ORX142, which is aimed at treating neurological and neurodegenerative disorders [1] - The milestone payment will be recognized as revenue in Q4 FY2025 [1] Company Overview - Nxera Pharma is a technology-driven biopharma company focused on developing specialty medicines to address unmet medical needs in Japan and globally [3] - The company operates a new-generation commercial business in Japan, developing and commercializing innovative medicines, with several products already launched [3] - Nxera Pharma utilizes its proprietary NxWave™ GPCR structure-based drug discovery platform to advance a comprehensive pipeline, both internally and in collaboration with leading pharmaceutical and biotech companies [3] - The company has key operational locations in Tokyo, Osaka, London, Cambridge, Basel, and Seoul, and is listed on the Tokyo Stock Exchange under the ticker 4565 [3]